|
|
Volumn 105, Issue 21, 2013, Pages 1590-1592
|
|
Risks of PSA screening now better understood.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PROSTATE SPECIFIC ANTIGEN;
TUMOR MARKER;
AGE;
AMBULATORY CARE;
BLOOD;
CLINICAL TRIAL (TOPIC);
DECISION MAKING;
EARLY DIAGNOSIS;
EVIDENCE BASED MEDICINE;
HUMAN;
LABORATORY DIAGNOSIS;
MALE;
MASS SCREENING;
PATIENT EDUCATION;
PRACTICE GUIDELINE;
PREDICTIVE VALUE;
PROSTATIC NEOPLASMS;
RISK;
SENSITIVITY AND SPECIFICITY;
STANDARDS;
TIME;
TRENDS;
UNITED STATES;
UNNECESSARY PROCEDURE;
AGE FACTORS;
CLINICAL TRIALS AS TOPIC;
DECISION MAKING;
EARLY DETECTION OF CANCER;
EVIDENCE-BASED MEDICINE;
FALSE POSITIVE REACTIONS;
HUMANS;
MALE;
MASS SCREENING;
OFFICE VISITS;
PATIENT EDUCATION AS TOPIC;
PRACTICE GUIDELINES AS TOPIC;
PREDICTIVE VALUE OF TESTS;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
RISK;
SENSITIVITY AND SPECIFICITY;
TIME FACTORS;
TUMOR MARKERS, BIOLOGICAL;
UNITED STATES;
UNNECESSARY PROCEDURES;
|
|
EID: 84891590207
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djt328 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
